

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
1301 MCKINNEY, SUITE 5100
HOUSTON, TEXAS 77010-3095
WWW.FULBRIGHT.COM

FACSIMILE: 713-651-5246

TELEPHONE: 713-651-5151

Date: January 2, 2002

No. of pages (including cover): 3

Matter No.: 09906355

TO

Examiner Chen
Facsimile No.: 703-746-7189

FROM

Melissa Sistrunk
Phone No.: 713-651-3735
User ID: 1533 Floor: 38

COMMENTS

Per your request, please see attached re USSN 09/585,645; atty.docket
P01899US2. Thank you.

If you experience any problems with this transmission or have questions, please call the sender.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	ZOGHBI et al.	§	Atty Docket: P01899US2
Application No.:	09/585,645	§	Customer No. 26271
Filing Date:	June 1, 2000	§	Group Art Unit: 1633
Title:	Compositions and Methods for the Therapeutic Use of an Atonal-Associated Sequence for Deafness, Osteoarthritis, and Abnormal Cell Proliferation	§	Examiner: C Qian
		§	(09906355 / OTA 99-47)

RESPONSE TO RESTRICTION REQUIREMENT
AND PRELIMINARY AMENDMENTS

Commissioner for Patents
Box Non-Fee Response
Washington D.C. 20231

Via U.S. Express Mail #EK102664439US

Dear Sir:

This is in response to the Office Action mailed September 14, 2001 in the above-referenced application. Applicants submit this response prior to October 14, 2001 in a timely manner.

Applicants herein elect Group IV of the restriction, with traverse, directed to claims 40-50 and 112-119, drawn to a method of generating hair cells and a composition comprising *atonal*-associated nucleic acid sequence.

Applicants herein cancel claims 1-39 and 51-111, but reserve the right to pursue these claims in subsequent prosecution.

Applicants herein submit the following new claims pursuant to Group IV:

120. A fusion protein comprising an *atonal*-associated amino acid sequence or fragment thereof and a desired amino acid sequence.

121. A nucleic acid sequence encoding the fusion protein of claim 120.


122. The method of claim 40, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

123. The composition of claim 112, wherein the composition further comprises an additional amino acid sequence or nucleic acid sequence that is not an *atonal*-associated nucleic acid sequence or amino acid sequence.

Support for new claims 120 and 121 is found, for example, on page 52, lines 5-12. Support for new claims 122 and 123 is found, for example, on page 58, lines 4-10; page 59, line 9 through page 61, line 12; and page 61, lines 15-23.

Applicants assert that no fees are due pursuant to the new claims in light of the cancellation of claims 1-39 and 51-111. If any fees are required, however, or if fees are deficient at any time during the prosecution of this application, please charge them to the standing account of Fulbright & Jaworski L.L.P. 06-2375, under Order No. 09906355.

Respectfully submitted,


Melissa L. Sistrunk
Reg. No. 45,579

Date: Oct. 10, 2001
Fulbright & Jaworski L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-3735